ArriVent BioPharma, Inc. (AVBP)
NASDAQ: AVBP · Real-Time Price · USD
30.17
-0.83 (-2.68%)
Aug 28, 2026, 4:00 PM EDT - Market closed
ArriVent BioPharma Stock Forecast
Stock Price Forecast
According to 11 analysts polled by S&P Global, ArriVent BioPharma stock has a consensus rating of "Strong Buy" and an average price target of $44.7. The average 1-year stock price forecast is 48.16% higher than the current stock price, while the lowest is $40 (+32.58%) and the highest is $50 (+65.73%).
Price Target: $44.7 (+48.16%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for ArriVent BioPharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 12 | 12 | 12 | 12 | 11 | 11 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 12 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $47 | Buy | Reiterates | $47 | +55.78% | Aug 17, 2026 |
| Citi | Citi | Buy Maintains $43 → $40 | Buy | Maintains | $43 → $40 | +32.58% | Aug 14, 2026 |
| Guggenheim | Guggenheim | Buy Reiterates $45 | Buy | Reiterates | $45 | +49.15% | Aug 13, 2026 |
| Truist Financial | Truist Financial | Buy Maintains $45 | Buy | Maintains | $45 | +49.15% | Aug 13, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $50 | Buy | Maintains | $50 | +65.73% | Aug 13, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
29.70M
EPS This Year
-4.34
from -4.32
EPS Next Year
-3.81
from -4.34
EPS and Forward PE are based on non-GAAP adjusted numbers.